anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute Promyelocytic Leukaemia (APL) has been known as a type of cancer, seriously endangering human health especially for young adults. It is of great significance to improve its eradication rate. Recent clinical trials show that ATRA plus ATO treatment regimen can result in complete response (CR) in 90-94% of patients and 5-year disease-free survival (DFS) in more than 90% of patients.

However, the ATRA plus ATO treatment regimen can achieve considerate survival rate, patients still need to receive infusion therapy in hospital. If oral arsenic can replace intravenous ATO without reduction of the efficacy, patients would not need to be administered to receive treatment, which would highly increase their quality of lives. The research and development of oral arsenic has therefore become a hotpoint. Professor Huang, Shilin from he 210th Hospital of PLA, according to the Prescription Theory "Jun Chen Zuo Shi", developed and designed an oral arsenic, the Compound Realgar-Indigo Naturalis Formula. Phase I, II Clinical trials have verified the security and efficacy of the Compound Realgar-Indigo Naturalis Formula. Research Team led by Professor Huang, Saijun, Shanghai Institute of Haematology (China), studied Compound Realgar-Indigo Naturalis Formula's mechanism of action from vitro cell lines and mice.

In the following Phase II clinical trial, APL patients received Compound Realgar-Indigo Naturalis Formula solo treatment regime. It resulted in 96.7% of CR and high safety rate Compound Realgar-Indigo Naturalis Formula was approved by the China Food and Drug Administration in 2009. Investigators have done a multi-centre, randomized, controlled, non-inferiority phase 3 clinical trial in China. 242 newly diagnosed APL patients (with newly diagnosed WBC\<50×10\^9/L) were enrolled. And the result showed that oral arsenic plus retinoic acid has an anti-leukaemic efficacy similar to the intravenous arsenic treatment.
Compn. based on surgically usable, polymerisable, monomer or polymer or mixture of both, contains up to 20% by wt. of basic mass of a Bi-contng. glass, the Bi-content thereof, expressed as Bi2O3, being 20 to 90 wt.%. The glass may also contain a dye, clouding agent and/or fluorescing agent. The glass may be coated with a size to improve adhesion thereof to the polymer.
Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).

Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.

Serum Concentration-Effect Relationship:

Bronchodilation occurs over the serum theophylline concentration range of 5-20 mcg/mL. Clinically important improvement in symptom control has been found in most studies to require peak serum theophylline concentrations > 10 mcg/mL, but patients with mild disease may benefit from lower concentrations. At serum theophylline concentrations > 20 mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining peak serum theophylline concentrations between 10 and 15 mcg/mL will achieve most of the drug's potential therapeutic benefit while minimizing the risk of serious adverse events.
PCT No. PCT/US95/01696 Sec. 371 Date Jan. 21, 1997 Sec. 102(e) Date Jan. 21, 1997 PCT Filed Feb. 8, 1995 PCT Pub. No. WO95/21864 PCT Pub. Date Aug. 17, 1995The invention relates to a composition comprising antibodies or binding portions thereof which bind to a naturally occurring or recombinant G-CSF receptor extracellular domain, and reduce tyrosine phosphorylation of a JAK molecule. The invention also relates to methods of using this composition for inhibiting or decreasing tyrosine phosphorylation of a JAK kinase and for inhibiting or decreasing G-CSF interaction with its receptor. Also described are antibodies which bind to a G-CSF receptor extracellular domain and which are produced by immunizing an animal with cells transfected with DNA encoding a G-CSF receptor.
The present invention discloses a soft capsule preparation with an extract of the effective part of a Tibetan medicine-lamiophlomis as the main raw material and a preparation method thereof. The extract of the effective part of the soft capsule of the present invention can be obtained by the methods of extraction by boiling with water, ethanol reflux, extraction by percolation, etc., and the extract is separated and purified by the methods of extraction by an organic solvent, adsorption with a macroporous resin, etc.; a suspending agent-beeswax and the fine powder of the extract are added into soybean oil and are uniformly mixed; the mixture is pressed by a colloidal mill to form the soft capsule preparation of the present invention. The soft capsule of the present invention has the preferable functions of alleviating pain and stopping bleeding. The soft capsule can be used for stopping bleeding, alleviating pain, resisting bacteria, relieving inflammation and activating blood circulation to dissipate blood stasis clinically. The soft capsule also has the advantages of quick disintegration in the gastrointestinal track, quick absorption and effect, little dosage, high biological availability, outstanding curative effect, high stability, etc.
The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide QLX-227-13, and a preparation method and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO. 13. The antibacterial peptide is obtained from high-throughput screening by a computer, and the antibacterial peptide with specific attribute can be generated by introducing preset functional attribute information, and is different from the existing antibacterial peptide in the nature, so that the defect of limited amino acid sequence arrangement of the natural antibacterial peptide is overcome. The strain is obtained through strict detection and screening of in-vitro and in-vivo antibacterial performance, hemolytic toxicity and cytotoxicity, has broad-spectrum antibacterial activity on gram-positive multi-drug resistant bacteria and/or gram-negative multi-drug resistant bacteria, and has good safety. The antibacterial peptide consists of 14 amino acids, has short peptide chain, mature preparation method and technology and low synthesis cost.
Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutions. The Devers Drop Device (D3) will accurately track when a patient removes an eye drop bottle cap, communicate usage data wirelessly to a database that researchers can access, and send alerts to patients when a medication is due. In addition to helping patients maintain their dosing schedule, the D3 will also provide adherence information to researchers and eye care providers, which will help to understand poor treatment outcomes and to develop improved treatment strategies.The clinical benefits of the device in improving adherence will initially be assessed and targeted towards glaucoma, but the ability of the device to be attached to all FDA-approved eye drop bottle caps will make this device attractive to all patients that need consistent daily use of eye drops.

Randomized, prospective clinical trial: The investigators will enroll 50 participants (25 male, 25 female) into a prospective trial with duration of up to 50 days. The inclusion criteria are those who are prescribed latanoprost eye drop to be used once per day at bedtime, and own a functioning Android or Apple iphone smartphone (iOs) with Bluetooth and cellular connectivity. The investigators will exclude patients who currently use smartphone medication reminders and those with severe cognitive impairment limiting their ability to understand a questionnaire. The 50-day period is useful for glaucoma studies because patients revert to their normal dosing pattern within two weeks after their last visit. This study will include two stages: Stage 1) a 25-day period evaluating baseline patient adherence with the D3 device; and Stage 2) a subsequent 25-day period to determine the effect of no reminder versus daily reminder using the D3 app, which includes integrated audio and visual reminders.
In the era of bare metal stent (BMS), the restenosis rate was about 25%. The introduction of drug-eluting stent (DES) reduces restenosis rate to 4%-10%. Neointimal hyperplasia and restenosis remain to be problems after DES implantation. Besides, DES causes an increase in uncovered struts, late stent thrombosis, neoatherosclerosis, and heterogeneous neointima. Diabetes mellitus (DM) results in increased risk for atherosclerosis, in-stent restenosis, neoatherosclerosis and late-stent thrombosis. Nicorandil, a hybrid of adenosine triphosphate-sensitive potassium (K-ATP) channel opener and nitrates, has been shown to reduce target vessel revascularization after stent implantation, target lesion revascularization after rotational atherectomy, and restenosis in patients undergoing percutaneous coronary intervention (PCI). Intracoronary optical coherence tomography(OCT) has emerged as a high-resolution imaging method for analysis of neointima that grows over the stent. We aim to examine the effect of nicorandil on the neointima after coronary DES implantation in patients with unstable angina and DM.
Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
Aim is to compare the efficiency of sorted subpopulation of CD34+/CXCR4+ cells and unselected bone-marrow-derived progenitor cells in treatment of patients with acute myocardial infarction and low left ventricular ejection fraction. The subpopulation of CD34+/CXCR4+ cells most likely contains the tissue-specific stem cells likely to be involved in myocardial salvage/regeneration after ischemic injury. This approach is novel and original, because so far no study identified the type of cells that actually contribute to stem cell-induced improvement in myocardial function in patients with AMI which were treated with unselected population of cells. The REGENT trial (prospective, randomized, multicentre trial comparing unselected BM mononuclear cells and sorted CD34/CXCR4+ cells in patients with myocardial infarction and low left ventricular ejection fraction) successfully treated with primary percutaneous coronary angioplasty within 12 hours after the onset of chest pain. The cells are delivered by intracoronary infusion. Efficiency is assessed by cardiac magnetic resonance imaging, echocardiography and left ventricular angiography.
Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
PURPOSE: A composition containing Ligularia stenocephala extract, fraction, or compound isolated from the same is provided to relieve, prevent, and treat obesity-related diseases. CONSTITUTION: A composition with an activity of removing peroxynitrite contains Ligularia stenocephala extract, fraction, or compound isolated from the same as an active ingredient. The extract is prepared by isolating with water, low alcohol of C1-4, and mixture solvent. The low alcohol is methanol. The fraction is a butanol fraction or ether fraction. The composition is a cosmetic, food, or pharmaceutical composition.
The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in 10 male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased threefold following coadministration of fluvoxamine.

Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses.

Therefore, fluvoxamine and thioridazine should not be coadministered [see Contraindications ( 4)] .
AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.
<P>PROBLEM TO BE SOLVED: To provide tablets of high dietary fiber content, to provide essential oil-containing dietary fiber-containing tablets, and to provide respective methods for producing these tablets.  <P>SOLUTION: A method for producing sodium alginate-containing tablets comprising compressing sodium alginate powder is provided. A 2nd version of the method for producing sodium alginate-containing tablets comprising infiltrating the above tablets with essential oil is provided. The sodium alginate-containing tablets produced by these methods are thus provided. By these methods, as sodium alginate can be made into tablets by direct powder compression, the tablets containing sodium alginate alone can be prepared, therefore obtaining the tablets high in dietary fiber content per unit amount. Besides, as compared to other tablet-forming methods, these methods are advantageous in terms of fewer steps and of needing no high temperature. Furthermore, the tablets thus obtained are highly compatible with the essential oil, being suppressed in oil segregation, that is, the essential oil is held stably in the tablets.  <P>COPYRIGHT: (C)2007,JPO&INPIT
1382766 Purifying 7-dimethylamino-6-demethyl-6-deoxytetracycline AMERICAN CYANAMID CO 13 Feb 1973 [11 May 1972] 7044/73 Heading C2C The invention comprises (i) a novel complex of minocycline hydrochloride (i.e. 7-dimethylamino - 6 - demethyl - 6 -deoxytetracycline hydrochloride) and calcium chloride, having the formula wherein n is an integer from 7 to 13; and (ii) a process for purifying minocycline hydrochloride by reacting it in aqueous solution with calcium chloride in a ratio of 0À3 to 1À2 moles of calcium chloride per mole of minocycline hydrochloride at a pH of 3À1 to 4À2 to precipitate the aforesaid complex, separating the complex from the solution and regenerating the minocycline hydrochloride by subjecting the complex to a metathesis reaction. The formation of the complex is preferably effected in the presence of 15-20% w/v. of an ionizable chloride salt (e.g. NaCl) which depresses the solubility of the complex and improves its yield. The metathesis reaction employs an acid forming an insoluble calcium salt (e.g. oxalic, lauric, palmitic, hydrofluoric or tartaric acid), which is removed to leave the purified minocycline solution. Reference has been directed by the Comptroller to Specification 1,003,474.
PURPOSE:To obtain a bioactive substance having carcinostatic activity by transplanting cancer cell to a mammal and subjecting the supernatant liquid of ascites of the mammal to Cohn fractionation. CONSTITUTION:A cancer cell is transplanted in the abdominal cavity of a mammal (e.g., mouse) and a carcinostatic agent (e.g., aclarubicin hydrochloride) is administered into the abdominal cavity. Spleen cell collected from the same kind of normal mammal is injected into the vein of said mammal and the ascites accumulated in the abdominal cavity is collected after a prescribed period (21-25 days after the transplantation). The cell residue existing in the collected ascites is removed by centrifugal separation, the supernatant liquid is concentrated by freeze-drying and the concentrate is subjected to Cohn fractionation. The objective bioactive substance having carcinostatic activity can be obtained as the 5th fraction. As an alternative method, the bioactive substance can be separated by the similar method from the ascites collected from the abdominal cavity of a cancerous patient ameliorated by immunosurveillance therapy.
The Human Papillomavirus (HPV) infection is responsible for more than 80% of reported cervical cancer and other virus-associated tumours. Although this global threat can be controlled using effective vaccination strategies, a growing perturbation of HPV infection is an emerging coinfection likely to increase the severity of the infection in humans. Moreover, these coinfections prolong the HPV infections, thereby risking the chances for oncogenic progression. The present review consolidated the clinically significant microbial coinfections/co-presence associated with HPV and their underlying molecular mechanisms. We discussed the gaps and concerns associated with demography, present vaccination strategies, and other prophylactic limitations. We concluded our review by highlighting the potential clinical as well as emerging computational intervention measures to kerb down HPV-associated severities.
Inform women of childbearing potential that ENVARSUS XR can harm the fetus. Instruct male and female patients to discuss with their healthcare provider family planning options including appropriate contraception. Also discuss with pregnant patients the risks and benefits of breastfeeding their infant [see Use in Specific Populations (8.1, 8.2, 8.3)].

Encourage female transplant patients who become pregnant and male patients who have fathered a pregnancy, exposed to immunosuppressants including tacrolimus, to enroll in the voluntary Transplantation Pregnancy Registry International. To enroll or register, patients can call the toll-free number 1-877-955-6877 or https://www.transplantpregnancyregistry.org.

Based on animal studies, ENVARSUS XR may affect fertility in males and females [see Nonclinical Toxicology (13.1)].
Coffin-Siris syndrome is an autosomal dominant disorder with neurological, cardiovascular, and gastrointestinal symptoms. Patients with Coffin-Siris syndrome typically have variable degree of developmental delay or intellectual disability, muscular hypotonia, dysmorphic facial features, sparse scalp hair, but otherwise hirsutism and fifth digit nail or distal phalanx hypoplasia or aplasia. Coffin-Siris syndrome is caused by pathogenic variants in 12 different genes including SMARCB1 and ARID1A. Pathogenic SMARCB1 gene variants cause Coffin-Siris syndrome 3 whereas pathogenic ARID1A gene variants cause Coffin-Siris syndrome 2. Here, we present two prenatal Coffin-Siris syndrome cases with autosomal dominant pathogenic variants: SMARCB1 gene c.1066_1067del, p.(Leu356AspfsTer4) variant, and a novel ARID1A gene c.1920+3_1920+6del variant. The prenatal phenotype in Coffin-Siris syndrome has been rarely described. This article widens the phenotypic spectrum of prenatal Coffin-Siris syndrome with severely hypoplastic right ventricle with VSD and truncus arteriosus type III, persisting left superior and inferior caval vein, bilateral olfactory nerve aplasia, and hypoplastic thymus. A detailed clinical description of the patients with ultrasound, MRI, and post mortem pictures of the affected fetuses showing the wide phenotypic spectrum of the disease is presented.
The invention discloses a method for predicting disease correlation in a biological correlation network, which comprises the following steps: S1. Establishing multi-nuclear representation of non-coding RNAand multi-nuclear representation of diseases,S2. The calculation method of central alignment is adopted to fuse the non-coding RNA polynuclear and the disease polynuclear respectively to obtain the optimal nuclear, S3. Singular value decomposition is used to decompose the fused optimal kernel into two matrices, S4. The hypergraph Laplacian matrix are obtained by calculating the matrix using the three matrix decomposition method of hypergraph regular term, S5. Calculate the Laplacian matrixof hypergraph by cross-validation, and obtain a new correlation matrix.
Background: Vancomycin-resistant enterococci (VRE) have become an increasing public health concern in the past few decades, being associated with serious multidrug-resistant (MDR) infections. This study was conducted to investigate the role of diarrheic pet animals as potential reservoirs for virulent extensively drug-resistant (XDR) VRE and their threat on human health. Materials and Methods: Rectal swabs were collected from 153 diarrheic pet animals (80 dogs and 73 cats). The collected swabs were cultured on CHROMagarTMVRE for the isolation of vancomycin-resistant Enterococcus faecalis and Enterococcus faecium, and then suspected colonies were identified as enterococci after Gram staining, conventional biochemical tests, and molecular techniques. VRE were basically identified using the disk diffusion method; however, molecular identification of vanA and vanB genes was carried out among confirmed VRE isolates. Moreover, three virulence genes (cytolysin A, cylA; enterococcal surface protein, esp; and hyaluronidase, hyl) were investigated in VRE isolates. Thereafter, VRE strains that harbored virulence genes were tested for antimicrobial susceptibility. Results: Eighteen out of 153 animals (11.8%) were positive for VRE, which were obtained from 15% and 8.2% of the examined dogs and cats, respectively. None of the obtained isolates carried the vanA gene, whereas the vanB gene was detected in E. faecalis (4/10) with a prevalence rate (40%). Of the obtained VRE isolates, five possessed esp and/or cylA, while all strains were negative for the hyl gene. Furthermore, four virulent VRE isolates exhibited an XDR pattern, and one isolate was MDR. Conclusion: Diarrheic pet animals could represent a potential zoonotic reservoir for virulent XDR vancomycin-resistant E. faecalis, which may have serious public health implications.
Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.